145 related articles for article (PubMed ID: 25082786)
1. MDM2 promotor polymorphism and disease characteristics in chronic lymphocytic leukemia: results of an individual patient data-based meta-analysis.
Benner A; Mansouri L; Rossi D; Majid A; Willander K; Parker A; Bond G; Pavlova S; Nückel H; Merkel O; Ghia P; Montserrat E; Kaderi MA; Rosenquist R; Gaidano G; Dyer MJ; Söderkvist P; Linderholm M; Oscier D; Tvaruzkova Z; Pospisilova S; Dührsen U; Greil R; Döhner H; Stilgenbauer S; Zenz T;
Haematologica; 2014 Aug; 99(8):1285-91. PubMed ID: 25082786
[TBL] [Abstract][Full Text] [Related]
2. MDM2 SNP309 promoter polymorphism, an independent prognostic factor in chronic lymphocytic leukemia.
Willander K; Ungerbäck J; Karlsson K; Fredrikson M; Söderkvist P; Linderholm M
Eur J Haematol; 2010 Sep; 85(3):251-6. PubMed ID: 20491880
[TBL] [Abstract][Full Text] [Related]
3. Lack of association between the MDM2 promoter polymorphism SNP309 and clinical outcome in chronic lymphocytic leukemia.
Kaderi MA; Mansouri M; Zainuddin N; Cahill N; Gunnarsson R; Jansson M; Kimby E; Aleskog A; Lundin J; Glimelius B; Melbye M; Juliusson G; Jurlander J; Rosenquist R
Leuk Res; 2010 Mar; 34(3):335-9. PubMed ID: 19573916
[TBL] [Abstract][Full Text] [Related]
4. MDM2 promoter SNP309 is associated with an increased susceptibility to chronic lymphocytic leukemia and correlates with MDM2 mRNA expression in Chinese patients with CLL.
Dong HJ; Fang C; Fan L; Zhu DX; Wang DM; Zhu HY; Zhuang Y; Miao KR; Liu P; Xu W; Li JY
Int J Cancer; 2012 May; 130(9):2054-61. PubMed ID: 21647873
[TBL] [Abstract][Full Text] [Related]
5. MDM2 SNP309 is associated with poor outcome in B-cell chronic lymphocytic leukemia.
Gryshchenko I; Hofbauer S; Stoecher M; Daniel PT; Steurer M; Gaiger A; Eigenberger K; Greil R; Tinhofer I
J Clin Oncol; 2008 May; 26(14):2252-7. PubMed ID: 18467716
[TBL] [Abstract][Full Text] [Related]
6. The MDM2 -309 T/G promoter single nucleotide polymorphism does not alter disease characteristics in chronic lymphocytic leukemia.
Zenz T; Häbe S; Benner A; Kienle D; Döhner H; Stilgenbauer S
Haematologica; 2008 Jul; 93(7):1111-3. PubMed ID: 18508789
[No Abstract] [Full Text] [Related]
7. MDM2 promotor polymorphism and disease characteristics in CLL.
Zenz T; Benner A; Stilgenbauer S
Leuk Res; 2010 May; 34(5):578-9. PubMed ID: 19709747
[No Abstract] [Full Text] [Related]
8. microRNA-34a expression correlates with MDM2 SNP309 polymorphism and treatment-free survival in chronic lymphocytic leukemia.
Asslaber D; Piñón JD; Seyfried I; Desch P; Stöcher M; Tinhofer I; Egle A; Merkel O; Greil R
Blood; 2010 May; 115(21):4191-7. PubMed ID: 20089965
[TBL] [Abstract][Full Text] [Related]
9. Role of the MDM2 promoter polymorphism (-309T>G) in acute myeloid leukemia development.
Cingeetham A; Vuree S; Jiwatani S; Kagita S; Dunna NR; Meka PB; Gorre M; Annamaneni S; Digumarti R; Sinha S; Satti V
Asian Pac J Cancer Prev; 2015; 16(7):2707-12. PubMed ID: 25854351
[TBL] [Abstract][Full Text] [Related]
10. p53 pathway gene single nucleotide polymorphisms and chronic lymphocytic leukemia.
Lahiri O; Harris S; Packham G; Howell M
Cancer Genet Cytogenet; 2007 Nov; 179(1):36-44. PubMed ID: 17981213
[TBL] [Abstract][Full Text] [Related]
11. Prognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.
Post SM; Pant V; Abbas H; Quintás-Cardama A
Oncotarget; 2010 Jul; 1(3):168-174. PubMed ID: 21301048
[TBL] [Abstract][Full Text] [Related]
12. Associations of MDM2 SNP309, transcriptional activity, mRNA expression, and survival in stage I non-small-cell lung cancer patients with wild-type p53 tumors.
Chien WP; Wong RH; Cheng YW; Chen CY; Lee H
Ann Surg Oncol; 2010 Apr; 17(4):1194-202. PubMed ID: 19941079
[TBL] [Abstract][Full Text] [Related]
13. MDM2 SNP309, gene-gene interaction, and tumor susceptibility: an updated meta-analysis.
Wan Y; Wu W; Yin Z; Guan P; Zhou B
BMC Cancer; 2011 May; 11():208. PubMed ID: 21619694
[TBL] [Abstract][Full Text] [Related]
14. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
[TBL] [Abstract][Full Text] [Related]
15. Results based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.
Sun YF; Leu JD; Chen SM; Lin IF; Lee YJ
BMC Cancer; 2009 Jan; 9():13. PubMed ID: 19144119
[TBL] [Abstract][Full Text] [Related]
16. Comprehensive single nucleotide polymorphism study supports the role of MDM2 in p53-competent chronic lymphocytic leukemia.
Lucas DM; Byrd JC
J Clin Oncol; 2008 May; 26(14):2244-5. PubMed ID: 18467712
[No Abstract] [Full Text] [Related]
17. MDM2 promoter polymorphism is associated with increased susceptibility to hepatocellular carcinoma in Turkish population.
Akkiz H; Sümbül AT; Bayram S; Bekar A; Akgöllü E
Cancer Epidemiol; 2010 Aug; 34(4):448-52. PubMed ID: 20447891
[TBL] [Abstract][Full Text] [Related]
18. Combined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.
Schmidt MK; Tommiska J; Broeks A; van Leeuwen FE; Van't Veer LJ; Pharoah PD; Easton DF; Shah M; Humphreys M; Dörk T; Reincke SA; Fagerholm R; Blomqvist C; Nevanlinna H
Breast Cancer Res; 2009; 11(6):R89. PubMed ID: 20021639
[TBL] [Abstract][Full Text] [Related]
19. MDM2 SNP309T>G polymorphism with hepatocellular carcinoma risk: a meta-analysis.
Liu GY; Jiang DK; Shen SQ; Yu L
Arch Med Res; 2011 Feb; 42(2):149-55. PubMed ID: 21565629
[TBL] [Abstract][Full Text] [Related]
20. MDR-1 polymorphisms (G2677T and C3435T) in B-chronic lymphocytic leukemia: an impact on susceptibility and prognosis.
Penna G; Allegra A; Alonci A; Aguennouz M; Garufi A; Cannavò A; Gerace D; Alibrandi A; Musolino C
Med Oncol; 2011 Dec; 28(4):1549-54. PubMed ID: 20496015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
